While AD core fluid biomarkers, including Aβ, phosphorylated tau, along with additional markers such as total tau and neurofilament light, have provided valuable insights, conflicting findings for candidate inflammation biomarkers have been reported. This evidence concerns the gene MAPT and Alzheimer disease.